The CT2 committee is now open for new proposalsWorking parties are asked to discuss any new ideas for proposals during their working party meetings at the Annual Meeting, including the WP statistician. If your WP does not have an allocated statistician, Leiden based WPs should contact Ronald Brand and Paris based WPs should contact Myriam Labopin before 17th March 2015, to have an EBMT statistician allocated to the proposal.
The deadline for submission of proposals to the CT2 committee is 17th April 2015. Proposals will be reviewed by the CT2 committee before the June 2015 Board meeting.
Please consult the EBMT website for further information. If you have any questions about the proposal process, please contact email@example.com.
Ongoing Clinical TrialsThe EBMT Clinical Trials Office is currently working on two prospective clinical trials in addition to the older trials that are in long-term follow-up.
RACE (PI’s: Regis Peffault de Latour, Antonio M Risitano – Sponsor = EBMT, CTC = Astrid Hoeppener): A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anemia patients in France, Germany, Italy, Netherlands, Spain, Switzerland and the UK.
The CMV Prophylaxis trial (EBMT Steering Group: Per Ljungman, Rafael Duarte – Sponsor = Merck, CTC = Sue Philpott) is progressing well. At the end of February 2015, over 120 patients had been randomised into the trial.
Other trials are still in long term follow up and/or undergoing analysis.
EBMT 2015 Annual MeetingThe Clinical Trials Office staff will be attending the Annual Meeting in Istanbul.
Please come and visit us and view our posters at the EBMT booth. The CTO will also be presenting at the Data Managers Session: “What is necessary to provide good clinical data for a clinical trial”.
We look forward to seeing you in Istanbul!